TOKYO -- The Tokyo Metropolitan Government plans to conduct clinical trials of the anti-parasitic drug Ivermectin at metropolitan and public hospitals to assess its effectiveness against COVID-19, Nikkei has learned.
Clinical trials will be conducted on patients with mild symptoms. Patients who are hospitalized mostly have moderate or serious symptoms. The metropolitan government will finalize the details of the study, including the size and duration of clinical trials, after the infection situation settles down.
